Johnson & Johnson Deliberately Avoids $100B GLP-1 Weight-Loss Drug Market

According to foreign media outlets such as The Globe and Mail and Foreign Policy, Johnson & Johnson is deliberately bypassing the GLP-1 weight-loss drug market, which has an overall valuation exceeding $100 billion.

It is reported that Johnson & Johnson CEO Joaquin Duato has clearly stated that he has no intention of chasing the weight-loss drug trend, but instead prefers to focus on oncology and medical device businesses.

This decision stands in stark contrast to Eli Lilly’s strategy, which has heavily invested in GLP-1 drugs and thereby become a Wall Street favorite. Currently,Weight Loss MedicationAccounting for nearly two-thirds of total revenue.

Novo Nordisk is also a major player in the GLP-1 field, with several other pharmaceutical companies racing to develop such drugs.

Market enthusiasm for GLP-1 drugs is so intense that many investors now view a company’s involvement in this field as a prerequisite for serious consideration.

Duato refuted this logic, arguing that Johnson & Johnson’s diversified strategy across multiple healthcare sectors has laid a more resilient foundation for the company.

Could this, in fact, make it a more attractive long-term investment than Eli Lilly? This isThe Globe and Mail raised questions. In response, the author conducted further analysis.

First, Johnson & JohnsonRather than chasing trends in the weight-loss sector, the company is focusing on strengthening its existing areas of strength. One key focus is oncology, specifically cancer therapeutics. The company holds a dominant market position in bone cancer and lung cancer treatments, and has recently acquired a company with a highly promising prostate cancer drug candidate.

Meanwhile, unlike Eli Lilly, which appears to focus solely on its pharmaceutical business, Johnson & Johnson is not only one of the largest pharmaceutical companies in the world but also one of the largest medical device companies. Its medical device business focuses on products such as surgical supplies and artificial joints. Like pharmaceuticals, medical devices are typically essential necessities. This business segment enables Johnson & Johnson to offer investors diversified investment opportunities that pure-play pharmaceutical companies cannot provide.

Furthermore, Eli Lilly’s stock price has surged significantly, driven by its leading position in GLP-1 medications. Its price-to-earnings (P/E) ratio exceeds 40x, compared to Johnson & Johnson’s P/E ratio of 29x. While it is inaccurate to characterize Johnson & Johnson’s stock as cheap, it is clearly valued lower than Eli Lilly’s. Additionally, Johnson & Johnson offers a more attractive dividend yield of 2.1%, whereas Eli Lilly’s stands at just 0.6%.

The authors ultimately concluded that, overall, Johnson & Johnson appears more attractive for investment than Eli Lilly, despite its choice to steer clear of the hot new drugs heavily favored by investors. Yet sometimes, a low-profile strategy can yield substantial returns for long-term investors, particularly those with an income-oriented focus.